Given reports of RVV effectiveness, we hypothesize that herd immunity is responsible for the inability to detect a significant difference between RVV-immunized and non-immunized children in our highlyvaccinated cohort.
INTRODUCTION
Prior to the introduction of rotavirus vaccine (RVV) in 2006, rotavirus (RV) was the most common cause of acute gastroenteritis (AGE) among children under 5 years of age in the United States [1] . Recent surveillance data and several post-licensure studies have shown significant reductions in RV disease activity and RV-related healthcare encounters [2, 3] . In this report, we examine the effectiveness of RVV in preventing hospital-related AGE outcomes in a highly vaccinated urban cohort of children enrolled in a pediatric practice-based research network.
MATERIALS AND METHODS

Study Design
A retrospective cohort study was performed evaluating the effectiveness of RVV in preventing AGE emergency department (ED) visits and hospitalizations during the first two full RV seasons after RVV introduction.
Study Setting
The CHOP network includes 33 ambulatory pediatric practices, of which 5 are located within 2 miles of CHOP's main hospital. These practices refer >90% of children to CHOP's main hospital for emergency care and hospitalization [4] and use the EpicCare (Verona, WI) electronic health record (EHR). The CHOP main hospital is a tertiary care pediatric hospital with over 24,000 inpatient admissions and 70,000 ED visits annually. All CHOP ED visits and hospitalizations are captured in the EHR.
Study Populations
The study population included any child born between February 22, 2006 (RotaTeq® licensure date; RotaTeq® was the only RVV available in the US during the study period) and February 29, 2008 , who had at least one visit at one of the 5 selected sites prior to 2 months of age. 
Exposures and Outcomes
The exposure was receipt of any number of doses of RVV (1, 2 or 3); unexposed patients received zero RVV doses. The primary outcomes were AGE-related ED visits and hospitalizations, defined as any ED or hospital encounter with a diagnosis code for a diarrheal illness using the AGE ICD-9-CM codes: 001 -005, 006 -007, 008 -008.5, 008.6, 008.61, 008.8, 009 -009.3, 558.9, 787 -787.03, 787.91 [5] . Outcomes were not assessed until the child was 6 weeks of age (earliest recommended age for RVV administration).
Data Collection
The EHR was queried to identify total numbers of AGE ED visits and hospitalizations, subject demographics, other immunizations received, complex chronic conditions (CCC) [6] , and numbers of primary care sick and preventative visits.
Statistical Methods
We characterized cohort subjects by all potential risk factors. We compared demographic variables and healthcare utilization between RVV-immunized and non-immunized groups using chi-square analysis for categorical variables and student's t test for continuous variables. We conducted univariable analyses using Poisson regression to determine associations between potential risk factors and outcomes.
For the multivariable analysis, we estimated the association between RVV exposure and the outcomes for each season using Poisson regression. All potential confounders and risk factors with a p value < 0.2 on univariable analysis were included in the multivariable model. We used a stratified analysis to assess effect modification.
Vaccine effectiveness (VE) in preventing AGE outcomes was calculated using the formula: VE = (1-Incident Rate Ratio (IRR)) × 100, where IRR is the adjusted ratio for each AGE outcome among vaccinated versus unvaccinated subjects [7] .
RESULTS
Characteristics of the Study Population
The study population included 2 cohorts: 3278 children in the 2007 cohort and 2705 children in the 2008 cohort. Among the 2007 cohort, 62% received at least 1 RVV dose and 43% were fully vaccinated with 3 doses. For the 2008 cohort, 88% received at least 1 dose and 63% received 3 doses. Demographic characteristics of children in the 2 cohorts were similar except non-vaccinated children in the 2008 cohort were more likely to be black (70.6% vs. 80%, p = 0.003). Non-vaccinated children had lower rates of healthcare utilization than their vaccinated peers; this disparity was more pronounced in the 2008 cohort. In 2007 and 2008, respectively 60% and 44% of RVV-immunized children were up-to-date with recommended preventative care visits, whereas 39% and 6% of non-immunized children were up-to-date (p values < 0.0001).
AGE ED Visits and Hospitalizations
For both cohorts, there was a trend toward protection for RVV-immunized children against AGE ED visits and hospitalizations. However, the only statistically significant protective effect was seen for the 2007 cohort in the 2008 season against hospitalizations (IRR 0.33, 95% CI (0.11, 0.96)) with a VE of 67% ( Table 1) .
Sub-analyses demonstrated that the 3-dose regimen was most protective against AGE hospitalizations in the youngest age group (those 6 weeks of age at entry into the first RV season) for the 2007 cohort in season 2008 (IRR = 0.21, 95% CI (0.06, 0.82), VE 79%) compared with 1 (IRR = 0.48, 95% CI (0.05, 4.29)) or 2 doses (IRR = 0.42, 95% CI (0.09, 1.95)). There was no significant protective vaccination effect in the older age groups regardless of RVV dose number for either outcome.
DISCUSSION
In this cohort study of an urban pediatric healthcare network with high rates of vaccination, we found a significant reduction in AGE hospitalizations among RVVimmunized children in the 2008 season. We demonstrated by age and dose-stratified analysis that the 3-dose RVV regimen was most effective in preventing AGE hospitalizations among the youngest children in the 2007 cohort during the second RV season.
For AGE hospitalizations, RVV-immunized children from the 2007 cohort were protected in the 2008 season with VE of 67%. This finding is similar to other cohort studies which demonstrated VE ranging from 59% - 
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There were several limitations for this study. By using AGE as an outcome, we cannot truly assess the reduction in RV disease due to RVV. However, viral stool pathogen testing was not uniformly conducted so we could not capture RV-specific disease as a retrospective outcome. Despite previous validation, identifying AGE outcomes using ICD-9-CM codes, may introduce bias due to error in both physician diagnosis and the recording of codes. Also, we used retrospective data and only captured ED visits and hospitalizations at CHOP's main hospital. If parents sought care for their children elsewhere, our data capture may be incomplete.
